Kornitzer Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Kornitzer Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$987K	Sell	2,210 -35	-2%	-$16.3K	0.02%	396
2025 Q4	$1.02M	Sell	2,245 -230	-9%	-$99.1K	0.02%	402
2025 Q3	$969K	Buy	2,475 +775	+46%	+$324K	0.02%	399
2025 Q2	$757K	Buy	1,700 +1,032	+154%	+$476K	0.02%	421
2025 Q1	$324K	Buy	668 +3	+0.5%	+$1.4K	0.01%	443
2024 Q4	$268K	Sell	665 -1,308	-66%	-$606K	0.01%	457
2024 Q3	$918K	Sell	1,973 -1	-0.1%	-$480	0.02%	396
2024 Q2	$925K	Buy	1,974 +237	+14%	+$103K	0.02%	397
2024 Q1	$726K	Hold	1,737	–	–	0.01%	420
2023 Q4	$707K	Sell	1,737 -550	-24%	-$203K	0.01%	411
2023 Q3	$795K	Sell	2,287 -1,275	-36%	-$446K	0.02%	413
2023 Q2	$1.25M	Hold	3,562	–	–	0.02%	379
2023 Q1	$1.12M	Hold	3,562	–	–	0.02%	386
2022 Q4	$1.03M	Hold	3,562	–	–	0.02%	393
2022 Q3	$1.03M	Hold	3,562	–	–	0.02%	400
2022 Q2	$1M	Buy	3,562 +900	+34%	+$241K	0.02%	406
2022 Q1	$695K	Buy	+2,662	New	+$632K	0.01%	455
2017 Q3	–	Sell	-156,835	Closed	-$20.2M	–	475
2017 Q2	$20.2M	Sell	156,835 -265	-0.2%	-$31.9K	0.35%	92
2017 Q1	$17.2M	Buy	+157,100	New	+$13.8M	0.31%	106

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Kornitzer Capital Management's VRTX Position: Q1 2026 in Review

Kornitzer Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 1.6% in Q1 2026, selling an estimated $16.3K and leaving 2,210 shares worth $987K. The position accounts for 0.02% of the portfolio, ranked #396.

Kornitzer Capital Management first reported a position in VRTX in Q1 2017 and has held it in 19 quarters since. The position peaked at $20.2M in Q2 2017. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Kornitzer Capital Management held 2,210 shares of Vertex Pharmaceuticals worth $987K as of Q1 2026.
Kornitzer Capital Management sold 35 Vertex Pharmaceuticals shares in Q1 2026, an estimated $16.3K.
Vertex Pharmaceuticals made up 0.02% of Kornitzer Capital Management's portfolio in Q1 2026, its #396 holding.
Kornitzer Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2017 and has held it in 19 quarters since.
Kornitzer Capital Management's Vertex Pharmaceuticals position peaked at $20.2M in Q2 2017.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Kornitzer Capital Management's 13F filing for Q1 2026, filed 30 Apr 2026.